Neuraxis Inc (NRXS)

Jan 13, 2025, 9:00 AM EST - 4 days ago

NeurAxis Inc. Issues Letter to Shareholders

Jan 6, 2025, 9:00 AM EST - 11 days ago

NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Nov 15, 2024, 2:04 PM EST - 2 months ago

NeurAxis, Inc (NRXS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:10 AM EST - 2 months ago

NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues

Oct 22, 2024, 9:00 AM EDT - 3 months ago

NeurAxis Announces New CPT® Category I Code for Percutaneous Electrical Nerve Field Stimulation

Sep 19, 2024, 9:00 AM EDT - 4 months ago

NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Aug 27, 2024, 9:00 AM EDT - 5 months ago

NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024

Aug 13, 2024, 9:00 AM EDT - 5 months ago

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

Aug 11, 2024, 5:44 AM EDT - 5 months ago

NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:00 AM EDT - 5 months ago

NeurAxis Reports Second Quarter 2024 Financial Results

Jun 7, 2024, 9:00 AM EDT - 8 months ago

NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

May 22, 2024, 1:34 PM EDT - 8 months ago

NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript

May 22, 2024, 8:00 AM EDT - 8 months ago

NeurAxis Reports First Quarter 2024 Financial Results

May 21, 2024, 9:00 AM EDT - 8 months ago

NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 15, 2024, 4:30 PM EDT - 8 months ago

NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024

Apr 23, 2024, 9:00 AM EDT - 9 months ago

NeurAxis Announces New Medical Policy Coverage in North Dakota

Apr 9, 2024, 6:45 PM EDT - 10 months ago

NeurAxis, Inc. (NRXS) Q4 2023 Earnings Call Transcript

Apr 9, 2024, 4:05 PM EDT - 10 months ago

NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Apr 1, 2024, 4:15 PM EDT - 10 months ago

NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024

Mar 27, 2024, 9:00 AM EDT - 10 months ago

NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry

Mar 11, 2024, 9:00 AM EDT - 11 months ago

NeurAxis Announces Highmark BCBS Policy Coverage

Mar 4, 2024, 9:00 AM EST - 11 months ago

NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage

Feb 27, 2024, 11:00 AM EST - 11 months ago

NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Jan 31, 2024, 9:00 AM EST - 1 year ago

NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

Dec 20, 2023, 9:00 AM EST - 1 year ago

NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer

Nov 20, 2023, 5:30 PM EST - 1 year ago

NeurAxis Reports Third Quarter 2023 Financial Results

Nov 15, 2023, 9:00 AM EST - 1 year ago

NeurAxis Announces CareFirst BCBS Policy Coverage

Nov 14, 2023, 9:00 AM EST - 1 year ago

NeurAxis Secures $3 Million Financing

Nov 8, 2023, 9:00 AM EST - 1 year ago

NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device

Sep 21, 2023, 8:00 AM EDT - 1 year ago

NeurAxis Reports Second Quarter 2023 Financial Results

Sep 13, 2023, 9:00 AM EDT - 1 year ago

NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase

Sep 12, 2023, 9:00 AM EDT - 1 year ago

NeurAxis Announces Publication of Prospective Study Showing IB-Stim™ Improves Quality of Life of Adolescents with IBS

Aug 29, 2023, 9:00 AM EDT - 1 year ago

NeurAxis Highlights Pediatric Post-Concussion Clinical Study

Aug 24, 2023, 9:00 AM EDT - 1 year ago

NeurAxis Highlights Strength of its Board of Directors

Aug 22, 2023, 9:00 AM EDT - 1 year ago

NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome

Aug 17, 2023, 9:02 AM EDT - 1 year ago

NeurAxis Announces Over $8 Million in IB-Stim™ Revenue

Aug 15, 2023, 9:00 AM EDT - 1 year ago

NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023

Aug 12, 2023, 6:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: IPO Market Sees Fitness, Liquor Marketing, And Medical Devices

ANL FTEL NWGL VFS

Aug 11, 2023, 9:30 AM EDT - 1 year ago

Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.

Aug 9, 2023, 10:00 AM EDT - 1 year ago

NeurAxis Announces Pricing of Initial Public Offering

Jul 29, 2023, 6:15 AM EDT - 1 year ago

U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs

ELWS FTEL GPCR INHD JNVR PRZO PXDT

Jul 21, 2023, 6:20 AM EDT - 1 year ago

Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously

Jan 27, 2023, 3:08 PM EST - 2 years ago

Neuraxis Seeks $15 Million IPO For Device Expansion

Jan 12, 2023, 3:12 PM EST - 2 years ago

Neuraxis Begins $33 Million U.S. IPO Effort